Generic Medicine Info
Should be taken with food.
Hypersensitivity. Treatment-experienced patient on haemodialysis. Mild to moderate (w/ ritonavir) and severe (w/ or w/o ritonavir) hepatic impairment. Lactation. Concomitant use w/ statins (e.g. simvastatin, lovastatin), antiarrhythmics (e.g. amiodarone, bepridil, quinidine, systemic lidocaine), antihistamines (e.g. astemizole, terfenadine), antipsychotics (e.g. pimozide, quetiapine), ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergometrine), GI prokinetics (e.g. cisapride), sedative and hypnotics (e.g. triazolam, oral midazolam), α1-adrenergic antagonists (e.g. alfuzosin), sildenafil (for treatment of pulmonary arterial HTN), irinotecan, and indinavir.
Special Precautions
Patient w/ haemophilia A/B, pre-existing cardiac conduction disorder (e.g. 1st-3rd degree AV or complex bundle branch block), DM, bradycardia, long congenital QT, electrolyte imbalance. Hepatic impairment (including chronic hepatitis B or C). Pregnancy. Monitoring Parameters Perform LFTs before and during treatment. Monitor viral load, CD4, blood lipids and glucose, and bilirubin. Monitor ECG esp in patient w/ pre-existing prolonged PR interval.
Adverse Reactions
Jaundice, GI disturbance (e.g. abdominal pain, diarrhoea, nausea, vomiting, dyspepsia), headache, insomnia, peripheral neurological symptoms, ocular icterus, asthenia, fatigue; mild to moderate rash (e.g. maculopapular rash), cholelithiasis, nephrolithiasis; hyperbilirubinaemia, elevated amylase, lipase, and liver enzymes, low neutrophils; lipodystrophy (e.g. central obesity, dorsocervical fat enlargement, peripheral wasting, breast enlargement, cushingoid appearance); insulin resistance, hyperglycaemia, hyperlactataemia; elevated creatine phosphokinase, myalgia, myositis; osteonecrosis, Grave's disease, immune reconstitution syndrome. Rarely, rhabdomyolysis.
Potentially Fatal: Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions, drug rash w/ eosinophilia and systemic symptoms (DRESS); PR interval prolongation. Rarely, QT prolongation, torsade de pointes.
Drug Interactions
Decreased concentration w/ PPIs, efavirenz, nevirapine, and rifampicin. May increase serum concentration of inhaled fluticasone and salmeterol.
CIMS Class
ATC Classification
J05AE08 - atazanavir ; Belongs to the class of protease inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on atazanavir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in